|
|
News Breaks | | | | November 13, 2012 | | 15:01 EDT |  | PRGO, CPIX | Perrigo confirms settlement of generic version of Acetadote patent litigation
Perrigo (TASE) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote injection brought by Cumberland Pharmaceuticals (CPIX). Under the terms of the settlement, Perrigo can launch a generic version of Acetadote injection upon expiration of the patents in May 2026. In addition, Perrigo entered into an agreement with Cumberland wherein Perrigo can distribute Cumberland sourced authorized generic product upon generic market formation. Acetadote injection, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury and has annual sales of approximately $41M, as measured by Wolters Kluwer. Perrigo's Chairman and CEO Joseph C. Papa stated, "This settlement is another example of our long-term investment in extended product development. As always, Perrigo is committed to making quality healthcare more affordable for our customers." | |
|
News For PRGO;CPIX From The Last 14 Days Check below for free stories on PRGO;CPIX the last two weeks. |
|
|
| May 20, 2013 | | 07:34 EDT |  | CPIX | UBS to host a conference
 Subscribe for More Information | | | May 13, 2013 | | 10:58 EDT |  | PRGO | High option volume stocks: PRGO OMEX SCTY OPTR DNR
Subscribe for More Information | | | May 8, 2013 | | 14:55 EDT |  | PRGO | Perrigo weakness creates buying opportunity, says Barrington
Subscribe for More Information | |
|
|
|
|
|
|
